Brought to you by 
Merck gains US rights to CSL's Afluria flu vaccine
01 Oct 2009
Executive Summary
Australia's CSL Ltd. has granted Merck exclusive rights to sell its Afluria seasonal influenza vaccine in the US for the 2010/2011-2015/2016 flu seasons.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck gains US rights to CSL's Afluria flu vaccine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice